Mirvetuximab soravtansine in the ovarian cancer treatment landscape: influence of prior taxane exposure on outcomes

By afschroeder • September 8, 2025

Smick AH, Brennan L, Silverstein J, Salani R, Konecny G, Chase DM. Mirvetuximab soravtansine in the ovarian cancer treatment landscape: influence of prior taxane exposure on outcomes. Int J Gynecol Cancer. 2025 Jul 23;35(10):102016. doi: 10.1016/j.ijgc.2025.102016. Epub ahead of print. PMID: 40916321.

Tags: antibody-drug conjugate, Fellow, Hematology/Oncology, Mirvetuximab soravtansine, Platinum-Resistant Ovarian Cancer, Publications, real-world evidence, Taxane Sequencing

Single-agent mosunetuzumab in older or unfit patients with previously untreated DLBCL: results of a phase 1/2 trial

Olszewski AJ, Avigdor A, Babu S, Levi I, Eradat H, Abadi U, Holmes H, McKinney MS, Woszczyk D, Giannopoulos K, Jurczak W, Jing J, Li[...]

Personalizing cancer care for older adults

Ji J, Sedrak MS. Personalizing cancer care for older adults. J Gerontol A Biol Sci Med Sci. 2026 Jun 6;81(7):glag126. doi: 10.1093/gerona/glag126. PMID: 42329168; PMCID:[...]

Receptor discordance between primary tumors and nodal metastases and correlation with the 21-gene recurrence score in early-stage, estrogen receptor-positive, node-positive breast cancer

Zheng S, Sullivan P, Vadehra K, Kim J, Levee A, Callahan R, Teshome M, Tseng CH, Bardia A, Kapoor NS. Receptor discordance between primary tumors[...]